Photo: darnitsa.ua Studies have not confirmed the efficacy of hydroxychloroquine in the treatment of coronavirus
The project on production of drugs from hydroxychloroquine was initiated in March after the inclusion of drugs in the treatment protocols of coronavirus in many countries.
The largest pharmaceutical company Darnitsa, Ukraine announced the suspension of the project for the production of hydroxychloroquine for the treatment of coronavirus infection COVID-19, reported the press service of the company.
This decision was made in connection with medical studies, which confirmed the efficacy of hydroxychloroquine in the treatment of coronavirus.
At the moment there are about 201 this study, five of which were completed.
“Darnitsa takes into account the global scientific thought as the safety of patients and the scientific feasibility is an absolute priority for the company. Therefore, the company has suspended the project for the production of the drug hydroxychloroquine for the treatment of COVID-19”, – said in a statement.
The project on production of drugs from hydroxychloroquine was started in March on the basis of Chinese treatment protocols and publications in authoritative sources about the effectiveness of the drug for the treatment of COVID-19. Hydroxychloroquine was also included in the experimental protocols of treatment of coronavirus in many countries, including in Ukraine, USA and European countries.
“At the same time, the center has received numerous requests from Ukrainian doctors and patients to give the opportunity to use a drug for the treatment of coronavirus infection, since this therapy was considered by the medical community as potentially effective”, – stated in the message.
On the basis of scientific data and handling of the medical community, the center launched a project to prepare for the production of preparations of hydroxychloroquine exclusively for the needs of medical institutions in the treatment COVID-19. Open sale of the drug was not provided.
Despite the suspension of the project, in case of need the company is ready to start producing this drug for patients with rheumatoid arthritis and systemic lupus erythematosus.
We will remind, in connection with the pandemic coronavirus Darnitsa changed production plans to ensure the provision of antiviral and antipyretic agents. In particular has started additional production Immostate and Paracetamol-Darnitsa.
News from the Reporter.net Telegram. Subscribe to our channel https://t.me/korrespondentnet